A New Antiviral against Covid-19 Nirmatrelvir plus Ritona | UPDATES IN MEDICINE
A New Antiviral against Covid-19
Nirmatrelvir plus Ritonavir for Covid-19
Nirmatrelvir is an Mpro inhibitor active against SARS-CoV-2 and is given with ritonavir, a pharmacokinetic enhancer. In this double-blind, placebo-controlled trial, nirmatrelvir plus ritonavir, when given within 5 days after symptom onset to patients at high risk for disease progression, decreased the risk of Covid-19–related hospitalization or death by 87.8%.
